Nucleoside Metabolic Inhibitor [EPC]

202703 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE AZACITIDINE CAPECITABINE CYTARABINE CLOFARABINE NELARABINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE PENTOSTATIN

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 18604
1 DEATH 15053
2 NAUSEA 13621
3 NEUTROPENIA 11028
4 FEBRILE NEUTROPENIA 10932
5 VOMITING 10771
6 DISEASE PROGRESSION 10045
7 FATIGUE 9758
8 PYREXIA 9650
9 THROMBOCYTOPENIA 8251
See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY 144 0.8623
1 ACUTE MYELOID LEUKAEMIA RECURRENT 503 0.4318
2 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 157 0.4099
3 CAECITIS 166 0.3689
4 MYELODYSPLASTIC SYNDROME TRANSFORMATION 178 0.3640
5 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 6117 0.3605
6 NEUTROPENIC COLITIS 402 0.3298
7 MYCOBACTERIUM CHELONAE INFECTION 154 0.3182
8 TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA 126 0.3111
9 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 306 0.3009
See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]